MedTrace Logo

Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB1,IB2,IIA1)

NCT04929769 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 780

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IB1, IB2, IIA1).

Conditions

Interventions

OTHER

Total Laparoscopic or Robotic Radical Hysterectomy

Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.

OTHER

Total Abdominal Radical Hysterectomy

Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.

Sponsors & Collaborators

  • Children's Hospital of Fudan University

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Taizhou Hospital, Affiliated Cancer Hospital of the University of Chinese Academy of Sciences

    collaborator UNKNOWN

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Obstetrics & Gynecology Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Xin Wu, PHD · The Obstetrics and Gynecology Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-07
Primary Completion
2024-09-07
Completion
2026-09-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04929769 on ClinicalTrials.gov